Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730247 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Liza Villaruz, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02730247 is a Phase 2 study that has completed, run by Liza Villaruz, MD. The registered enrollment target is 7 participants.
The verdict
NCT02730247, a Phase 2 study, has completed, sponsored by Liza Villaruz, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The subjects who take part in this clinical research study have advanced non-small cell lung cancer (NSCLC) that has been previously treated with other drugs. If they join this study, they would receive ramucirumab (Cyramza ®) in combination with nab-paclitaxel (Abraxane®). Ramucirumab given with nab-paclitaxel is considered an investigational drug combination to use in this type of cancer because giving these two drugs together has not been approved by any regulatory authority like the US Food and Drug Administration (FDA) for NSCLC cancer. Ramucirumab works by slowing or stopping the growth of cancer cells. Nab-Paclitaxel works by blocking the ability of cancer cells to break down the internal 'skeleton' that allows them to divide and multiply. With the skeleton still in place, the cells cannot divide and they eventually die.
Interventions
- DRUG nab-paclitaxel
- DRUG ramucirumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-07-05 |
| Est. Completion | 2019-09-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730247
The ClinicalTrials.gov registry entry for NCT02730247 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Liza Villaruz, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which nab-paclitaxel is the first listed.
NCT02730247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02730247 about?
NCT02730247 is a clinical study titled "Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)". The subjects who take part in this clinical research study have advanced non-small cell lung cancer (NSCLC) that has been previously treated with other drugs. If they join this study, they would receive ramucirumab (Cyramza ®) in combination with nab-paclitaxel (Abraxane®). Ramucirumab given with na...
What is the current status of trial NCT02730247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2017-07-05. Estimated completion is 2019-09-08.
What interventions are being tested in trial NCT02730247?
The interventions under investigation include: nab-paclitaxel (DRUG), ramucirumab (DRUG).
Who is sponsoring clinical trial NCT02730247?
This trial is sponsored by Liza Villaruz, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.